Emiliano Fabiani

List of Publications by Year
in descending order

54	1,059	361045 20	433756 31
papers	citations	h-index	g-index

56	56	56	1671
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonal haematopoiesis as a risk factor for therapyâ€related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemoâ€(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	1.2	7
2	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis. Frontiers in Oncology, 2022, 12, 871590.	1.3	16
3	In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome. Platelets, 2021, 32, 378-382.	1.1	2
4	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. Biology, 2021, 10, 128.	1.3	5
5	Whatâ€™s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood, 2021, 138, 749-757.	0.6	23
6	Mutational profile of ZBTB16â€RARAâ€positive acute myeloid leukemia. Cancer Medicine, 2021, 10, 3839-3847.	1.3	9
7	Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood, 2021, 138, 1331-1344.	0.6	19
8	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. Leukemia and Lymphoma, 2020, 61, 979-982.	0.6	1
9	Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. Blood Cancer Journal, 2020, 10, 85.	2.8	9
10	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. Blood, 2020, 136, 19-20.	0.6	1
11	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers, 2019, 11, 1373.	1.7	13
12	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Leukemia Research, 2019, 84, 106191.	0.4	5
13	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. Cancers, 2019, 11, 865.	1.7	22
14	Could haemochromatosis (<scp>HFE</scp>) gene mutations affect response to iron chelation in myelodysplastic syndrome? â€“ Response to Lucijanic and Kusec. British Journal of Haematology, 2019, 186, 639-640.	1.2	1
15	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. British Journal of Haematology, 2019, 186, e100-e103.	1.2	2
16	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (<scp>MDS</scp>). British Journal of Haematology, 2019, 185, 954-957.	1.2	4
17	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia, 2019, 33, 785-790.	3.3	33
18	Longitudinal detection of DNMT3A^{R882H} transcripts in patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, E120-E123.	2.0	7

#	Article	IF	Citations
19	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. Pharmacogenomics Journal, 2018, 18, 444-449.	0.9	2
20	Therapy-related myeloid neoplasms: clinical perspectives. OncoTargets and Therapy, 2018, Volume 11, 5909-5915.	1.0	12
21	Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center. Blood, 2018, 132, 3617-3617.	0.6	0
22	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Molecular and Clinical Oncology, 2017, 8, 463-465.	0.4	4
23	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. Oncotarget, 2017, 8, 84074-84085.	0.8	4
24	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	0.8	22
25	A case of SRSF2 mutation in chronic lymphocytic leukemia. Leukemia Research Reports, 2016, 6, 11-14.	0.2	2
26	Impairment of PI3K/AKT and WNT/Î²-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Experimental Hematology, 2016, 44, 75-83.e4.	0.2	42
27	Characteristics and outcome of therapyâ€related myeloid neoplasms: Report from the <scp>I</scp>talian network on secondary leukemias. American Journal of Hematology, 2015, 90, E80-5.	2.0	93
28	Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia. Neoplasia, 2015, 17, 401-409.	2.3	24
29	Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer Journal, 2015, 5, e323-e323.	2.8	32
30	Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 85-89.	1.2	1
31	Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 1675-1675.	0.6	0
32	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. Leukemia and Lymphoma, 2014, 55, 2942-2944.	0.6	4
33	TheBCL2L10Leu21Arg variant and risk of therapy-related myeloid neoplasms andde novomyelodysplastic syndromes. Leukemia and Lymphoma, 2014, 55, 1538-1543.	0.6	22
34	Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica, 2014, 99, 613-619.	1.7	61
35	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. Experimental Hematology, 2014, 42, 731-733.	0.2	4
36	Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. OncoTargets and Therapy, 2014, 7, 1043.	1.0	9

#	Article	IF	Citations
37	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. Haematologica, 2014, 99, e152-e153.	1.7	16
38	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia, 2013, 27, 982-985.	3.3	22
39	Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics, 2013, 8, 210-219.	1.3	24
40	Myelodysplastic Stem Cells: Gene Expression Profiling. Stem Cells and Cancer Stem Cells, 2012, , 55-67.	0.1	0
41	5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011011.	0.5	5
42	Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. Leukemia Research, 2011, 35, 465-471.	0.4	11
43	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia, 2011, 25, 1910-1913.	3.3	40
44	SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011052.	0.5	8
45	Epigenetic changes in therapy-related MDS/AML. Chemico-Biological Interactions, 2010, 184, 46-49.	1.7	36
46	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells, Molecules, and Diseases, 2010, 45, 181-185.	0.6	28
47	Analysis of genome-wide methylation and gene expression induced by 5-aza-2â€²-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 2275-2284.	0.6	43
48	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2009, 15, 5002-5007.	3.2	103
49	P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes. Leukemia Research, 2009, 33, S139-S140.	0.4	0
50	Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leukemia Research, 2009, 33, 1068-1071.	0.4	23
51	PU.1 and CEBPA expression in acute myeloid leukemia. Leukemia Research, 2008, 32, 1448-1453.	0.4	16
52	Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia, 2008, 22, 1685-1691.	3.3	36
53	Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Annals of Oncology, 2007, 18, 1523-1528.	0.6	61
54	Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. British Journal of Cancer, 2006, 95, 1108-1113.	2.9	69